Kim, G A
Rim, T H
Lee, S C
Byeon, S H
Koh, H J
Kim, S S
Lee, C S
Article History
Received: 27 August 2014
Accepted: 12 February 2015
First Online: 8 May 2015
Competing interests
: One of the authors, Dr Hyoung Jun Koh, has financial conflict about ranibizumab. He has received grants for clinical research from Novartis, served as an advisor for Novartis, Bayer, and Allergan, and served as a speaker for Santen. The other authors have no proprietary or commercial interest in any materials discussed in this article.